EPA+DHA Clinical Trials Related to the Prevention or Treatment of COVID-19

GOED is aware of 14 clinical trials underway studying EPA+DHA consumption in the prevention or treatment of COVID-19. For ease of tracking, we have only included studies that are listed in clinical trials databases.

  1. GOED member KD Pharma Group, working with partner SLA Pharma, has started a clinical trial with its EPA-based drug candidate EPAspire to treat patients with symptoms of COVID-19. [Study link]
  2. GOED member Pharmavite will supply supplements to the Icahn School of Medicine at Mount Sinai in New York to examine whether EPA and DHA have an effect on new-onset olfactory dysfunction in COVID-19 patients. [Study link]
  3. Omega-3 wound care product manufacturer Kerecis and the National Hospital of Iceland are conducting a clinical trial investigating the effectiveness of Kerecis’ Omega3 Viruxide system on COVID-19 patients. Doctors in Italy are already using the product off-label to spray into the oral and nasal cavities of patients believed to have early onset of COVID-19. [Study link]
  4. Amarin and Kaiser Permanente's MITIGATE COVID-19 trial will study the effects of Vascepa on COVID-19 and other viral upper respiratory infection (URI)-related morbidity and mortality in a high-risk cohort of adults with atherosclerotic cardiovascular disease (ASCVD). [Study link]
  5. Amarin is also conducting a trial sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group on the effects of four grams of Vascepa twice daily for three days, then two grams twice daily for 11 days on key inflammatory markers in COVID-19 patients. [Study link]
  6. The PREPARE-IT trial between Harvard University, the Cardiovascular Institute of Rosario and Argentina's Latin American Clinical Studies will test the hypothesis that eight grams daily of EPA will reduce the risk of COVID-19 contagion by 30% in 1500 Argentine healthcare workers. [Study link]
  7. Jordan's Applied Science Private University is testing whether 300 mg/day of EPA and DHA given to uninfected Jordanian test subjects for two months will significantly affect their interleukin levels compared to the control group. [Study link]
  8. Salmon oil producer Hofseth BioCare has entered into a Phase 2 clinical trial to evaluate the ability of its OmeGo salmon oil to reduce Acute Respiratory Distress Syndrome (ARDS) related to COVID-19. [Study link]
  9. The Sabzevar University of Medical Sciences in Iran is examining whether omega-3 supplementation improves inflammatory and biochemical markers on critically ill COVID-19 patients. [Study link]
  10. King Saud University in Saudi Arabia is investigating the effects of Abbott's Oxepa supplement, which includes EPA, on the disease. [Study link]
  11. Brazil’s Bahia State University is studying the effects of a daily supplement with L-arginine, nucleotides and omega-3s on the inflammatory response of COVID-19 patients. [Study link]
  12. Sweden’s Karolinska University Hospital is testing whether supplementation with intravenous fish oil emulsion Omegaven can resolve inflammatory storms in COVID-19 patients. [Study link]
  13. Vall Hebron University in Barcelona will research whether parenteral fish oil is effective in reducing liver impairment in COVID-19 patients. [Study link]
  14. Groupe Hospitalier Paris Saint Joseph is studying whether eicosanoid levels measured at different stages of COVID-19 infection can provide a prognosis for the disease. [Study link]